Early combination therapy may be important to enhance glycemic control and delay islet cell failure. The therapeutic effect tends to decrease gradually with time when single medication is used. HbA1c level stage intervention: 1, HbA1c <6.5%: early stage of diabetes, can be prevented by lifestyle intervention, including diet, exercise therapy. 2.HbA1c in 6.5%-7.5%: single medication, while attention should be paid to the selection of drugs according to the mechanism of action to distinguish the strength of drug action, as well as the target of action on postprandial and fasting blood glucose; high postprandial blood glucose, can be treated with acarbose. 3.HbA1c in 7.5%-9.0%: dual drug use, combined drug use should be complementary and pay attention to reduce the occurrence of side effects. 4.HbA1c>9.0%: enable multi-drug combination or insulin therapy. In terms of control goals, there can be different glucose-lowering goals for different populations. In conclusion: the selection of glucose-lowering drugs needs to consider age, diabetes typing, body mass index, disease duration, blood glucose level, comorbidity and complication status, postprandial and fasting hyperglycemia type, lifestyle habits and economic status. Only then can the most appropriate individualized glucose-lowering treatment plan be selected.